Search Within

Neha Ratna

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (1)
Groups
  1. Department of Medicine (10)
  2. GSK Faculty (10)
  3. Genitourinary Oncology Service (10)
  4. Hematologic Malignancies, Division of (10)
  5. Human Oncology and Pathogenesis Program (10)
  6. Solid Tumor Oncology Division (10)

More Groups

People
  1. Ashley Regazzi (10)
  2. Gopakumar Iyer (10)
  3. David Aggen (9)
  4. David Solit (9)
  5. Dean Bajorin (9)
  6. Jonathan Rosenberg (9)

More People

Years
  1. 2024 (3)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (2)
  5. 2020 (2)
Publications
  1. Journal of Clinical Oncology (8)
  2. Cancer Research (1)
  3. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (8)
  2. American Association for Cancer Research (2)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: A real-world experience
    Journal Article

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Ratna, N.; Duzgol, C.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Regazzi, A. M.; Chen, Z.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Katims, A. B.; Lenis, A. T.; Shah, R. H.; Chu, C. E.; Ratna, N.; Regazzi, A. M.; Pietzak, E. J.; Aggen, D. H.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced/metastatic urothelial cancer
    Meeting Abstract

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Chen, Z.; Lattanzi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors
    Meeting Abstract

    Sarfaty, M.; Desjardins, C. A.; Giardina, P.; Bardhan, K.; Pandian, S.; Halley, K.; Halvorsen, E. M.; Callahan, M. K.; Postow, M. A.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Lenis, A. T.; Chen, Z.; Al-Ahmadie, H. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save